Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $4.9 billion.
Alpine develops immunotherapies to address cancer, kidney disease, and other serious autoimmune and inflammatory conditions by engineering proteins that influence the body’s immune response.
“This is a historic moment for Alpine, for our employees, and most importantly, for patients who may benefit from our pipeline of products,” said Mitchell Gold, the company’s CEO.